8-K: Cardiff Oncology Reports Positive Clinical Data and Financial Update for Q1 2024

Cardiff Oncology announced promising clinical trial results and a solid financial position, with a cash runway projected into Q3 2025.

Summary

• Cardiff Oncology released its first quarter 2024 financial results and provided a business update, highlighting positive clinical data for its lead drug, onvansertib.
• The company presented data at the AACR Annual Meeting supporting its first-line RAS-mutated mCRC strategy, showing strong efficacy in bev naive patients.
• The ONSEMBLE trial data replicated the bev naive signal from an earlier Phase 1b/2 trial, further substantiating the lead program in RAS-mutated mCRC.
• Preclinical data also suggests onvansertib's potential in RAS wild-type mCRC, small cell lung cancer, and ovarian cancer.
• Cardiff Oncology had $67.2 million in cash and equivalents as of March 31, 2024, with a projected cash runway into Q3 2025.
• The company expects an initial data readout from its first-line RAS-mutated mCRC trial in the second half of 2024.

Sentiment

Score: 8

Explanation: The document presents strong clinical data and a solid financial position, indicating a positive outlook for the company. The delay in the trial readout is a minor concern, but the overall tone is optimistic.

Positives

• The company has a strong cash position of $67.2 million, providing a runway into Q3 2025.
• Clinical data from the ONSEMBLE trial showed a 50% objective response rate in bev naive patients, indicating strong efficacy.
• Preclinical data suggests onvansertib's potential in multiple cancer types, including RAS wild-type mCRC, small cell lung cancer, and ovarian cancer.
• The company has reduced its operating expenses by $1.0 million compared to the same period in 2023.
• The company has a partnership with Pfizer Ignite for the clinical execution of the CRDF-004 trial.

Negatives

• The company experienced a net loss of $10.01 million for the quarter.
• The initial readout from the first-line RAS-mutated mCRC trial has been updated to the second half of 2024.

Risks

• Clinical trials are lengthy and expensive with uncertain outcomes, and results of earlier studies may not predict future results.
• Clinical trials may be suspended or discontinued due to unexpected side effects or safety risks.
• The company needs additional financing to continue operations.
• There are risks related to business interruptions, including epidemics, pandemics, and cyber-attacks.
• There are uncertainties of government or third-party payer reimbursement.
• The company depends on key personnel and has limited experience in marketing and sales.
• There is substantial competition in the biotechnology industry.
• There are uncertainties of patent protection and litigation.
• The company depends on third parties for various aspects of its operations.
• There are risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.

Future Outlook

The company anticipates a key data readout from its first-line trial in RAS-mutated mCRC in the second half of 2024, which could serve as a value inflection point. Contingent on the results of the Phase 2 trial, the company plans to initiate a Phase 3 trial with registrational intent.

Management Comments

• During the start of 2024, we presented several important new data sets supporting our first-line RAS-mutated mCRC strategy and the broader opportunity for onvansertib, said Mark Erlander, Ph.D., Chief Executive Officer of Cardiff Oncology.
• The data from the ONSEMBLE trial replicated, in a second independent and randomized dataset, the bev nave signal from our earlier Phase 1b/2 KRAS-mutated mCRC trial.
• Looking ahead, we believe that our upcoming data readout from our first-line trial in RAS-mutated mCRC has the potential to serve as a key value inflection point for our company and revolutionize the treatment of RAS-mutated mCRC, an area with no new treatments approved in over two decades.

Industry Context

This announcement is significant as it highlights the potential of onvansertib in addressing unmet needs in cancer treatment, particularly in RAS-mutated mCRC, where new therapies are lacking. The positive preclinical data in other cancer types also positions the company to expand its pipeline and address a broader market.

Comparison to Industry Standards

• The 50% objective response rate in bev naive patients in the ONSEMBLE trial is promising compared to standard of care treatments in mCRC.
• The odds ratio of 13.64 and hazard ratio of 0.21 in the onvansertib plus FOLFIRI/bev arm compared to bev exposed patients are statistically significant and suggest a substantial clinical benefit.
• The preclinical data showing onvansertib's activity in RAS wild-type mCRC, SCLC, and ovarian cancer is encouraging and could lead to new treatment options in these areas.
• Companies like Amgen and Mirati Therapeutics are also developing therapies for RAS-mutated cancers, but Cardiff Oncology's approach with PLK1 inhibition is distinct and could offer a different mechanism of action.

Stakeholder Impact

• Shareholders may see a positive impact due to the promising clinical data and extended cash runway.
• Employees may benefit from the company's progress and financial stability.
• Patients may have access to new treatment options if onvansertib is successful.
• Suppliers and creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• The company expects an initial data readout from its first-line RAS-mutated mCRC trial in the second half of 2024.
• Contingent upon the results of the Phase 2 trial, the company will initiate a Phase 3 trial with registrational intent.

Key Dates

Keywords

Onvansertib, mCRC, RAS-mutated, PLK1 inhibition, Clinical trial, Cancer, Metastatic colorectal cancer, SCLC, Ovarian cancer, AACR, Biotechnology, Phase 2, Phase 3, FOLFIRI, Bevacizumab, Chemotherapy